More fair, reliable criteria needed for cost-effectiveness of antihypertensive agents

The government will have to undertake controversial drug pricing and reimbursement policies despite opposition from pharmaceutical companies, according to the Korean Pharmacists for Democratic Society.

The civic group said in a recent statement that the Health Insurance Review and Assessment Service (HIRA) should introduce stricter standard for antihypertensive drugs to become eligible for c...